Lee Danner & Bass Inc. Sells 14,496 Shares of Pfizer Inc. (NYSE:PFE)

Lee Danner & Bass Inc. lessened its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 11.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 111,745 shares of the biopharmaceutical company's stock after selling 14,496 shares during the period. Lee Danner & Bass Inc.'s holdings in Pfizer were worth $2,965,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the stock. Goodman Financial Corp lifted its holdings in shares of Pfizer by 5.5% in the fourth quarter. Goodman Financial Corp now owns 432,271 shares of the biopharmaceutical company's stock worth $11,468,000 after acquiring an additional 22,609 shares during the last quarter. DCF Advisers LLC boosted its position in Pfizer by 49.5% in the fourth quarter. DCF Advisers LLC now owns 51,350 shares of the biopharmaceutical company's stock valued at $1,362,000 after buying an additional 17,000 shares in the last quarter. Douglass Winthrop Advisors LLC grew its stake in shares of Pfizer by 78.2% during the fourth quarter. Douglass Winthrop Advisors LLC now owns 85,776 shares of the biopharmaceutical company's stock worth $2,276,000 after buying an additional 37,653 shares during the last quarter. Northwest & Ethical Investments L.P. increased its holdings in shares of Pfizer by 0.6% during the fourth quarter. Northwest & Ethical Investments L.P. now owns 265,072 shares of the biopharmaceutical company's stock worth $7,032,000 after buying an additional 1,541 shares in the last quarter. Finally, Berkeley Capital Partners LLC lifted its stake in shares of Pfizer by 2.3% in the 4th quarter. Berkeley Capital Partners LLC now owns 69,190 shares of the biopharmaceutical company's stock valued at $1,836,000 after acquiring an additional 1,531 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Remove Ads

Pfizer Trading Down 0.6 %

Shares of Pfizer stock traded down $0.15 on Monday, hitting $26.13. 37,863,216 shares of the company's stock traded hands, compared to its average volume of 36,651,219. The company has a market capitalization of $148.21 billion, a price-to-earnings ratio of 18.53, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a fifty day moving average of $26.15 and a two-hundred day moving average of $27.02. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter last year, the firm earned $0.10 EPS. The company's quarterly revenue was up 24.7% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Bank of America restated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup cut their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Finally, UBS Group decreased their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $31.92.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.06% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.